The relationship between mTOR signalling pathway and recombinant antibody productivity in CHO cell lines

BMC Biotechnology

Volumn 14, Issue , 2014, Pages

  Edros, Raihana ^a   McDonnell, Susan ^a   Al Rubeai, Mohamed ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cell engineering; CHO; Monoclonal antibody; mTOR; Phosphotidylinositol 3 kinase

Indexed keywords

ANTIBIOTICS; CELL CULTURE; CELL DEATH; CELL ENGINEERING; CELL GROWTH; ENZYMES; GENE ENCODING; GROWTH KINETICS; METABOLISM; MONOCLONAL ANTIBODIES; POLYMERASE CHAIN REACTION; PRODUCTIVITY; RECOMBINANT PROTEINS; TRANSCRIPTION;

CHO; DIFFERENTIALLY EXPRESSED GENE; EXTRACELLULAR SIGNALS; MAMMALIAN TARGET OF RAPAMYCIN (MTOR); MTOR; NUTRIENT AVAILABILITY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTIDYLINOSITOL 3-KINASE;

GENE EXPRESSION REGULATION;

IMMUNOGLOBULIN G4; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE D1; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110 DELTA; PROTEIN S6; S6 KINASE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CELL DENSITY; CELL GROWTH; CELL SIZE; CHO CELL; ENZYME ACTIVE SITE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; CRICETULUS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME;

EID: 84896401049     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-14-15     Document Type: Article

References (84)

1. Walsh G. Biopharmaceutical benchmarks. Nat Biotechnol 2000, 18(8):831-3. 10.1038/78720, 10932150.
2. Walsh G. Biopharmaceutical benchmarks. Nat Biotechnol 2010, 28(9):917-24. 10.1038/nbt0910-917, 20829826.
3. Chu L, Robinson DK. Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 2001, 12(2):180-187. 10.1016/S0958-1669(00)00197-X, 11287235.
4. Seth G, Charaniya S, Wlaschin KF, Hu W-S. In pursuit of a super producer-alternative paths to high producing recombinant mammalian cells. Curr Opin Biotechnol 2007, 18:8.
5. Derouazi M, Girard P, Van Tilborgh F, Iglesias K, Muller N, Bertschinger M, Wurm FM. Serum-free large-scale transient transfection of CHO cells. Biotechnol Bioeng 2004, 87(4):537-545. 10.1002/bit.20161, 15286991.
6. Haldankar R, Li D, Saremi Z, Baikalov C, Deshpande R. Serum-free suspensin large-scale transient transfection of CHO cells in WAVE bioreactors. Mol Biotechnol 2006, 34(2):191-199. 10.1385/MB:34:2:191, 17172664.
7. Xing Z, Kenty BM, Li ZJ, Lee SS. Scale-up analysis for a CHO cell culture process in large-scale bioreactors. Biotechnol Bioeng 2009, 103(4):733-746. 10.1002/bit.22287, 19280669.
8. Lucas BK, Giere LM, DeMarco RA, Shen A, Chisholm V, Crowley CW. High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector. Nucleic Acids Res 1996, 24(9):1774-1779. 10.1093/nar/24.9.1774, 145850, 8649999.
9. Pu H, Cashion LM, Kretschmer PJ, Liu Z. Rapid establishment of high-producing cell lines using dicistronic vectors with glutamine synthetase as the selection marker. Mol Biotechnol 1998, 10(1):17-25. 10.1007/BF02745860, 9779420.
10. Hilal-Alnaqbi A, Hu A, Zhang Z, Al-Rubeai M. Growth, metabolic activity, and productivity of immobilized and freely suspended CHO cells in perfusion culture. Biotechnol Appl Biochem 2013, 60:436-445. 10.1002/bab.1103, 23701045.
11. Kaneko Y, Sato R, Aoyagi H. Evaluation of Chinese hamster ovary cell stability during repeated batch culture for large-scale antibody production. J Biosci Bioeng 2010, 109(3):274-280.
12. Konstantinov KB, Tsai Y, Moles D, Matanguihan R. Control of long-term perfusion chinese hamster ovary cell culture by glucose auxostat. Biotechnol Prog 2008, 12(1):100-109.
13. Kou TC, Fan L, Ye ZY, Zhou Y, Liu XP, Zhao L, Tan WS. Process analysis of reduced specific productivity of TNFR-Fc in Chinese hamster ovary cells at high cell density. Process Biochem 2011, 46(7):1492-1499.
14. Gasser F, Mulsant P, Gillois M. Long-term multiplication of the Chinese hamster ovary (CHO) cell line in a serum-free medium. In Vitro Cell Dev Biol Plant 1985, 21(10):588-592.
15. Haldankar R, Kopchick JJ, Ridgway D. Stable production of a human growth hormone antagonist from CHO cells adapted to serum,ÄêFree suspension culture. Biotechnol Prog 1999, 15(3):336-346. 10.1021/bp9900460, 10356250.
16. Sinacore M, Charlebois T, Harrison S, Brennan S, Richards T, Hamilton M, Scott S, Brodeur S, Oakes P, Leonard M. CHO DUKX cell lineages preadapted to growth in serum-free suspension culture enable rapid development of cell culture processes for the manufacture of recombinant proteins. Biotechnol Bioeng 2000, 52(4):518-528.
17. Dinnis DM, James DC. Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature?. Biotechnol Bioeng 2005, 91(2):180-189. 10.1002/bit.20499, 15880827.
18. Page MJ, Sydenham MA. High level expression of the humanized monoclonal antibody CAMPATH-1H in chinese hamster ovary cells. Nat Biotech 1991, 9(1):64-68.
19. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004, 22(11):1393-1398. 10.1038/nbt1026, 15529164.
20. Chusainow J, Yang YS, Yeo JH, Toh PC, Asvadi P, Wong NS, Yap MG. A study of monoclonal antibody-producing CHO cell lines: what makes a stable high producer?. Biotechnol Bioeng 2009, 102(4):1182-1196. 10.1002/bit.22158, 18979540.
21. Fann CH, Guarna MM, Kilburn DG, Piret JM. Relationship between recombinant activated protein C secretion rates and mRNA levels in baby hamster kidney cells. Biotechnol Bioeng 1999, 63(4):464-472. 10.1002/(SICI)1097-0290(19990520)63:4<464::AID-BIT10>3.0.CO;2-H, 10099627.
22. Gu MB, Todd P, Kompala DS. Metabolic burden in recombinant CHO cells: effect ofdhfr gene amplification andlacZ expression. Cytotechnology 1995, 18(3):159-166.
23. Jiang Z, Huang Y, Sharfstein ST. Regulation of recombinant monoclonal antibody production in chinese hamster ovary cells: a comparative study of gene copy number, mRNA level, and protein expression. Biotechnol Prog 2008, 22(1):313-318.
24. Kim SJ, Kim NS, Ryu CJ, Hong HJ, Lee GM. Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Biotechnol Bioeng 1998, 58(1):73-84. 10.1002/(SICI)1097-0290(19980405)58:1<73::AID-BIT8>3.0.CO;2-R, 10099263.
25. Pendse GJ, Karkare S, Bailey JE. Effect of cloned gene dosage on cell growth and hepatitis B surface antigen synthesis and secretion in recombinant CHO cells. Biotechnol Bioeng 1992, 40(1):119-129. 10.1002/bit.260400117, 18601052.
26. Kidane A, Guan Y, Evans P, Kaderbhai M, Kemp R. Comparison of heat flux in wild-type and genetically-engineered chinese hamster ovary cells. J Therm Anal Calorim 1997, 49(2):771-783.
27. Lloyd DR, Holmes P, Jackson LP, Emery AN, Al-Rubeai M. Relationship between cell size, cell cycle and specific recombinant protein productivity. Cytotechnology 2000, 34(1):59-70. 3449736, 19003381.
28. Carvalhal AV, Marcelino I, Carrondo MJT. Metabolic changes during cell growth inhibition by p27 overexpression. Appl Microbiol Biotechnol 2003, 63(2):164-173. 10.1007/s00253-003-1385-5, 12856162.
29. Khoo SH, Al-Rubeai M. Detailed understanding of enhanced specific antibody productivity in NS0 myeloma cells. Biotechnol Bioeng 2009, 102(1):188-199. 10.1002/bit.22041, 18683250.
30. Bi JX, Shuttleworth J, Al-Rubeai M. Uncoupling of cell growth and proliferation results in enhancement of productivity in p21CIP1-arrested CHO cells. Biotechnol Bioeng 2004, 85(7):741-749. 10.1002/bit.20025, 14991652.
31. Arsham AM, Neufeld TP. Thinking globally and acting locally with TOR. Curr Opin Cell Biol 2006, 18(6):589-97. 10.1016/j.ceb.2006.09.005, 17046229.
32. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004, 24(1):200-216. 10.1128/MCB.24.1.200-216.2004, 303352, 14673156.
33. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009, 10(5):307-18. 10.1038/nrm2672, 19339977.
34. Polak P, Hall MN. mTOR and the control of whole body metabolism. Curr Opin Cell Biol 2009, 21(2):209-18. 10.1016/j.ceb.2009.01.024, 19261457.
35. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7(8):606-19. 10.1038/nrg1879, 16847462.
36. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005, 17(6):596-603. 10.1016/j.ceb.2005.09.009, 16226444.
37. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441(7092):424-30. 10.1038/nature04869, 16724053.
38. Proud CG. mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun 2004, 313(2):429-36. 10.1016/j.bbrc.2003.07.015, 14684180.
39. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Sci Signal 2001, 294(5548):1942.
40. Peng T, Golub TR, Sabatini DM. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002, 22(15):5575-84. 10.1128/MCB.22.15.5575-5584.2002, 133939, 12101249.
41. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Sci Signal 2008, 320(5882):1496.
42. Christie GR, Hajduch E, Hundal HS, Proud CG, Taylor PM. Intracellular sensing of amino acids in xenopus laevis oocytes stimulates p70 S6 kinase in a target of rapamycin-dependent manner. J Biol Chem 2002, 277(12):9952-7. 10.1074/jbc.M107694200, 11788584.
43. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002, 277(27):23977-23980. 10.1074/jbc.C200171200, 11997383.
44. Chong WPK, Sim LC, Wong KTK, Yap MGS. Enhanced IFNγ production in adenosine-treated CHOCells: a mechanistic study. Biotechnol Prog 2009, 25(3):866-873. 10.1002/btpr.118, 19507259.
45. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science 2001, 294(5544):1102-5. 10.1126/science.1063518, 11691993.
46. Dreesen IA, Fussenegger M. Ectopic expression of human mTOR increases viability, robustness, cell size, proliferation, and antibody production of chinese hamster ovary cells. Biotechnol Bioeng 2011, 108(4):853-66. 10.1002/bit.22990, 21404259.
47. Browne SM, Al-Rubeai M. Analysis of an artificially selected GS-NS0 variant with increased resistance to apoptosis. Biotechnol Bioeng 2011, 108(4):880-92. 10.1002/bit.22994, 21404261.
48. O'Callaghan PM, McLeod J, Pybus LP, Lovelady CS, Wilkinson SJ, Racher AJ, Porter A, James DC. Cell line-specific control of recombinant monoclonal antibody production by CHO cells. Biotechnol Bioeng 2010, 106(6):938-951. 10.1002/bit.22769, 20589672.
49. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterol 2011, 140(3):1071-1083. e5.
50. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, Della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010, 28(2):245-255. 10.1200/JCO.2008.21.5988, 19917848.
51. Boller D, Schramm A, Doepfner KT, Shalaby T, von Bueren AO, Eggert A, Grotzer MA, Arcaro A. Targeting the phosphoinositide 3-kinase isoform p110δ impairs growth and survival in neuroblastoma cells. Clin Cancer Res 2008, 14(4):1172-81. 10.1158/1078-0432.CCR-07-0737, 18281552.
52. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005, 102(3):802-807. 10.1073/pnas.0408864102, 545580, 15647370.
53. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 2009, 29(6):1411-1420. 10.1128/MCB.00782-08, 2648237, 19114562.
54. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 2008, 10(8):935-945. 10.1038/ncb1753, 2711503, 18604198.
55. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141(2):290-303. 10.1016/j.cell.2010.02.024, 3024592, 20381137.
56. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005, 123(4):569-80. 10.1016/j.cell.2005.10.024, 16286006.
57. Kimball SR, Shantz LM, Horetsky RL, Jefferson LS. Leucine regulates translation of specific mRNAs in L6 myoblasts through mTOR-mediated changes in availability of eIF4E and phosphorylation of ribosomal protein S6. J Biol Chem 1999, 274(17):11647-11652. 10.1074/jbc.274.17.11647, 10206976.
58. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci 2001, 98(18):10314-10319. 10.1073/pnas.171076798, 56958, 11504908.
59. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004, 10(24):8421-8425. 10.1158/1078-0432.CCR-04-0941, 15623621.
60. Hayward BE, Hussain A, Wilson RH, Lyons A, Woodcock V, McIntosh B, Harris TJR. The cloning and nucleotide sequence of cDNA for an amplified glutamine synthetase gene from the Chinese hamster. Nucl Acids Res 1986, 14(2):999-1008. 10.1093/nar/14.2.999, 339478, 2868445.
61. Kalwy S, Rance J, Young R. Toward more efficient protein expression. Mol Biotechnol 2006, 34(2):151-156. 10.1385/MB:34:2:151, 17172660.
62. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
63. Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, Lin HC, Yancopoulos GD, Glass DJ. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005, 280(4):2737-2744.
64. Sanchezmargalet V, Goldfine ID, Vlahos CJ, Sung CK. Role of phosphatidylinositol-3-kinase in insulin receptor signaling: studies with inhibitor, LY294002. Biochem Biophys Res Commun 1994, 204(2):446-452. 10.1006/bbrc.1994.2480, 7980500.
65. Takai H, Wang RC, Takai KK, Yang H, de Lange T. Tel2 regulates the stability of PI3K-related protein kinases. Cell 2007, 131(7):1248-1259. 10.1016/j.cell.2007.10.052, 18160036.
66. Takai H, Xie Y, de Lange T, Pavletich NP. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. Genes Dev 2010, 24(18):2019-2030. 10.1101/gad.1956410, 2939364, 20801936.
67. Edros RZ, McDonnell S, Al-Rubeai M. Using molecular markers to characterize productivity in chinese hamster ovary cell lines. PLoS One 2013, 8(10):e75935. 10.1371/journal.pone.0075935, 3798306, 24146795.
68. Leevers SJ, Weinkove D, MacDougall LK, Hafen E, Waterfield MD. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J 1996, 15(23):6584-94. 452483, 8978685.
69. Luo J, McMullen JR, Sobkiw CL, Zhang L, Dorfman AL, Sherwood MC, Logsdon MN, Horner JW, DePinho RA, Izumo S. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 2005, 25(21):9491-9502. 10.1128/MCB.25.21.9491-9502.2005, 1265829, 16227599.
70. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000, 19(11):2537-2548. 10.1093/emboj/19.11.2537, 212739, 10835352.
71. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003, 3(4):371-377. 10.1016/S1471-4892(03)00071-7, 12901945.
72. Yee JC, Wlaschin KF, Chuah SH, Nissom PM, Hu WS. Quality assessment of cross-species hybridization of CHO transcriptome on a mouse DNA oligo microarray. Biotechnol Bioeng 2008, 101:1359-1365. 10.1002/bit.21984, 18814282.
73. Wlaschin KF, Nissom PM, Gatti Mde L, Ong PF, Arleen S, Tan KS, Rink A, Cham B, Wong K, Yap M, Hu WS. EST sequencing for gene discovery in Chinese hamster ovary cells. Biotechnol Bioeng 2005, 91:592-606. 10.1002/bit.20511, 16003777.
74. Fry MJ. Structure, regulation and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1994, 1226(3):237-68. 10.1016/0925-4439(94)90036-1, 8054357.
75. Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1998, 1436(1-2):127-50.
76. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23(18):3151-71. 10.1038/sj.onc.1207542, 15094765.
77. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002, 16(12):1472-1487. 10.1101/gad.995802, 186342, 12080086.
78. Brazzatti JA, Klingler-Hoffmann M, Haylock-Jacobs S, Harata-Lee Y, Niu M, Higgins MD, Kochetkova M, Hoffmann P, McColl SR. Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis. Oncogene 2012, 31(18):2350-61. 10.1038/onc.2011.414, 21996737.
79. Dogra C, Changotra H, Wergedal JE, Kumar A. Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch. J Cell Physiol 2006, 208(3):575-585. 10.1002/jcp.20696, 16741926.
80. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 2009, 28(8):1151-61. 10.1038/onc.2008.460, 19137016.
81. Avni D, Biberman Y, Meyuhas O. The 5′ terminal oligopyrimidine tract confers translational control on TOP mRNAs in a cell type-and sequence context-dependent manner. Nucleic Acids Res 1997, 25(5):995-1001. 10.1093/nar/25.5.995, 146534, 9023110.
82. Jefferies H, Reinhard C, Kozma S, Thomas G. Rapamycin selectively represses translation of the " polypyrimidine tract" mRNA family. Proc Natl Acad Sci 1994, 91(10):4441-4445. 10.1073/pnas.91.10.4441, 43801, 8183928.
83. Terada N, Patel HR, Takase K, Kohno K, Nairn AC, Gelfand EW. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci 1994, 91(24):11477-11481. 10.1073/pnas.91.24.11477, 45254, 7972087.
84. Kuroda A, Rauch TA, Todorov I, Ku HT, Al-Abdullah IH, Kandeel F, Mullen Y, Pfeifer GP, Ferreri K. Insulin gene expression is regulated by DNA methylation. PLoS One 2009, 4(9):e6953. 10.1371/journal.pone.0006953, 2735004, 19742322.